Source comparison
Melanotan-2 vs PDE5 Inhibitors: Mechanism Comparison
Primary Mechanism MC4R agonist in CNS; triggers central NO release PDE5 inhibitor; amplifies peripheral cGMP Melanotan-2 operates upstream. Bypasses need for baseline NO production Requires Sexual Arousal No. Central activation occurs independent of arousal Ye
This comparison does not assign a generated winner or score.
- Primary Mechanism
- MC4R agonist in CNS; triggers central NO release
- PDE5 inhibitor; amplifies peripheral cGMP
- Melanotan-2 operates upstream. Bypasses need for baseline NO production
- Requires Sexual Arousal
- No. Central activation occurs independent of arousal
- Yes. Requires arousal-triggered NO signal
- Central mechanism eliminates arousal dependency
- Onset Time
- 2–6 hours (peak 4–8 hours)
- 30–60 minutes
- Slower onset reflects multi-step cascade from CNS to periphery
- Duration of Effect
- 24–72 hours (intermittent episodes)
- 4–6 hours
- 24–36 hours
- Prolonged receptor occupancy extends effect window
- Efficacy in Treatment-Resistant ED
- 64% response in PDE5 inhibitor non-responders
- Baseline efficacy 60–70%; minimal in vascular impairment
- Baseline efficacy 60–70%; minimal in neurogenic ED
- Centrally mediated mechanism succeeds where peripheral interventions fail
- Common Side Effects
- Nausea (40–60%), spontaneous erections (70–80%)
- Headache (15–20%), flushing (10–15%)
- Headache (10–15%), dyspepsia (10%)
- MC4R-mediated nausea is the primary tolerability barrier